DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
Quintiles IMS Holdings, Inc. (“QuintilesIMS”) (NYSE: Q) today announced
the pricing of the offering of €420 million in gross proceeds of senior
notes to be issued by its wholly owned subsidiary, Quintiles IMS
Incorporated (the “Issuer”). The net proceeds from the notes offering,
together with proceeds from the previously announced amendment to the
Issuer’s senior secured credit facility (the “Amendment”), will be used
to refinance certain indebtedness of the Issuer, including the
redemption of its outstanding 4.125% euro-denominated senior notes due
2023, to pay down the Issuer’s revolving credit facility, to pay fees
and expenses related to the notes offering and the Amendment and for
other general corporate purposes, which may include share repurchases
and acquisitions.
The notes will bear interest at a rate of 2.875% and will pay interest
semi-annually in arrears on March 15 and September 15 of each year
beginning on March 15, 2018. The notes will mature on September 15,
2025. The issuance of the senior notes is expected to occur on or about
September 14, 2017, subject to customary closing conditions.
Certain statements in this press release are forward-looking statements.
These statements involve a number of risks, uncertainties and other
factors including the failure to consummate the notes offering and the
Amendment and potential changes in market conditions that could cause
actual results to differ materially.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy the notes. The notes have not been, and
will not be, registered under the Securities Act of 1933 and may not be
offered or sold in the United States absent registration or an
applicable exemption from the registration requirements of the
Securities Act of 1933. The notes are being offered only to qualified
institutional buyers in the United States in reliance on Rule 144A under
the Securities Act of 1933 and outside the United States only to
non-U.S. investors pursuant to Regulation S.
About QuintilesIMS
QuintilesIMS (NYSE:Q) is a leading integrated information and
technology-enabled healthcare service provider worldwide, dedicated to
helping its clients improve their clinical, scientific and commercial
results. Formed through the merger of Quintiles Transnational and IMS
Health, QuintilesIMS’s approximately 50,000 employees conduct operations
in more than 100 countries. Companies seeking to improve real-world
patient outcomes through treatment innovations, care provision and
access can leverage QuintilesIMS’s broad range of healthcare
information, technology and service solutions to drive new insights and
approaches. QuintilesIMS provides solutions that span clinical to
commercial, bringing customers a unique opportunity to realize the full
potential of innovations and advanced healthcare outcomes.
As a global leader in protecting individual patient privacy,
QuintilesIMS uses healthcare data to deliver critical, real-world
disease and treatment insights. Through a wide variety of
privacy-enhancing technologies and safeguards, QuintilesIMS protects
individual privacy while managing information to drive healthcare
forward. These insights and execution capabilities help biotech, medical
device and pharmaceutical companies, medical researchers, government
agencies, payers and other healthcare stakeholders in the development
and approval of new therapies, and to identify unmet treatment needs and
understand the safety, effectiveness and value of pharmaceutical
products in improving overall health outcomes.
QUINTILESIMSFIN
Click
here to subscribe to Mobile Alerts for QuintilesIMS.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170911006277/en/
Source: Quintiles IMS Holdings, Inc.